Ozmosi | Tipelukast Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Tipelukast

Alternative Names: tipelukast, mn-001
Clinical Status: Active
Latest Update: 2026-01-06
Latest Update Note: News Article

Product Description

Mechanisms of Action: LT Antagonist, PDE Inhibitor, 5-LOX Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: MediciNova
Company Location: Western America
Company CEO: Yuichi Iwaki
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tipelukast

Countries in Clinic: United States

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

  • Clinical Outcomes Reported - MediciNova presented P2 Fatty Liver|Fatty Liver, Alcoholic|Non-alcoholic Fatty Liver Disease results on 2024-05-28 for Tipelukast
  • Clinical Outcomes Reported - MediciNova presented P2 Non-alcoholic Fatty Liver Disease results on 2024-05-26 for Tipelukast

Highest Development Phases

Phase 2: Fatty Liver, Alcoholic|Hypertriglyceridemia|Liver Diseases, Alcoholic|Non-alcoholic Fatty Liver Disease|Type 2 Diabetes

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT05464784

MN-001-NATG-202

P2

Recruiting

Fatty Liver, Alcoholic|Type 2 Diabetes|Hypertriglyceridemia|Liver Diseases, Alcoholic|Non-alcoholic Fatty Liver Disease

2025-12-31

50%

2024-11-21

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments